{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T21:12:35Z","timestamp":1778015555131,"version":"3.51.4"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"crossref","award":["BO\/00232\/17\/5"],"award-info":[{"award-number":["BO\/00232\/17\/5"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Innovation and Technology, Hungary","award":["\u00daNKP-19-4"],"award-info":[{"award-number":["\u00daNKP-19-4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Autoimmun Highlights"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Unlike in other autoimmune liver diseases such as autoimmune hepatitis and primary biliary cholangitis, the role and nature of autoantigenic targets in primary sclerosing cholangitis (PSC), a progressive, chronic, immune-mediated, life threatening, genetically predisposed, cholestatic liver illness, is poorly elucidated. Although anti-neutrophil cytoplasmic antibodies (ANCA) have been associated with the occurrence of PSC, their corresponding targets have not yet been identified entirely. Genome-wide association studies revealed a significant number of immune-related and even disease-modifying susceptibility loci for PSC. However, these loci did not allow discerning a clear autoimmune pattern nor do the therapy options and the male gender preponderance in PSC support a pathogenic role of autoimmune responses. Nevertheless, PSC is characterized by the co-occurrence of inflammatory bowel diseases (IBD) demonstrating autoimmune responses. The identification of novel autoantigenic targets in IBD such as the major zymogen granule membrane glycoprotein 2 (GP2) or the appearance of proteinase 3 (PR3) autoantibodies (autoAbs) have refocused the interest on a putative association of loss of tolerance with the IBD phenotype and consequently with the PSC phenotype. Not surprisingly, the report of an association between GP2 IgA autoAbs and disease severity in patients with PSC gave a new impetus to autoAb research for autoimmune liver diseases. It might usher in a new era of serological research in this field. The mucosal loss of tolerance against the microbiota-sensing GP2 modulating innate and adaptive intestinal immunity and its putative role in the pathogenesis of PSC will be elaborated in this review. Furthermore, other potential PSC-related autoantigenic targets such as the neutrophil PR3 will be discussed. GP2 IgA may represent a group of new pathogenic antibodies, which share characteristics of both type 2 and 3 of antibody-mediated hypersensitive reactions according to Coombs and Gell.<\/jats:p>","DOI":"10.1186\/s13317-020-00129-x","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T14:07:01Z","timestamp":1584367621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia"],"prefix":"10.1186","volume":"11","author":[{"given":"Steffi","family":"Lopens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Milkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schierack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Wunsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Roggenbuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"issue":"6","key":"129_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis\u2014a comprehensive review. J Hepatol. 2017;67(6):1298\u2013323. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.022.","journal-title":"J Hepatol"},{"issue":"8","key":"129_CR2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weism\u00fcller","year":"2017","unstructured":"Weism\u00fcller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152(8):1975\u20131984.e8. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.038.","journal-title":"Gastroenterology"},{"key":"129_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jhep.2008.01.020","volume":"48","author":"TJ Weism\u00fcller","year":"2008","unstructured":"Weism\u00fcller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis\u2013aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48:38\u201357.","journal-title":"J Hepatol"},{"issue":"10139","key":"129_CR4","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(18)30300-3.","journal-title":"Lancet"},{"key":"129_CR5","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jhep.2008.01.020","volume":"48","author":"TJ Weism\u00fcller","year":"2008","unstructured":"Weism\u00fcller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis\u2014aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48:S38\u201357.","journal-title":"J Hepatol"},{"issue":"8","key":"129_CR6","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/j.1572-0241.2000.02267.x","volume":"95","author":"HJF Hoogstraten","year":"2000","unstructured":"Hoogstraten HJF, Vleggaar FP, Boland GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol. 2000;95(8):2015\u201322. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.02267.x.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"129_CR7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/hep.510230612","volume":"23","author":"KM Boberg","year":"1996","unstructured":"Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, Schrumpf E. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996;23(6):1369\u201376.","journal-title":"Hepatology"},{"issue":"2","key":"129_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1385\/CRIAI:28:2:093","volume":"28","author":"J Worthington","year":"2005","unstructured":"Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. CRIAI. 2005;28(2):93\u2013104. https:\/\/doi.org\/10.1385\/CRIAI:28:2:093.","journal-title":"CRIAI"},{"issue":"9","key":"129_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/hep4.1226","volume":"2","author":"L Adam","year":"2018","unstructured":"Adam L, Zoldan K, Hofmann M, et al. Follicular T helper cell signatures in primary biliary cholangitis and primary sclerosing cholangitis. Hepatol Commun. 2018;2(9):1051\u201363. https:\/\/doi.org\/10.1002\/hep4.1226.","journal-title":"Hepatol Commun"},{"key":"129_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaut.2015.08.016","volume":"66","author":"GJ Webb","year":"2016","unstructured":"Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun. 2016;66:25\u201339. https:\/\/doi.org\/10.1016\/j.jaut.2015.08.016.","journal-title":"J Autoimmun"},{"issue":"2","key":"129_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00054725-199805000-00026","volume":"4","author":"M Salmi","year":"1998","unstructured":"Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis. 1998;4(2):149\u201356.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"129_CR12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","volume":"33","author":"AJ Grant","year":"2001","unstructured":"Grant AJ, Lalor PF, H\u00fcbscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology. 2001;33(5):1065\u201372. https:\/\/doi.org\/10.1053\/jhep.2001.24231.","journal-title":"Hepatology"},{"issue":"9853","key":"129_CR13","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(12)60026-9.","journal-title":"Lancet"},{"issue":"9853","key":"129_CR14","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(12)60150-0.","journal-title":"Lancet"},{"issue":"7","key":"129_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/qjmed\/hch078","volume":"97","author":"FE Watt","year":"2004","unstructured":"Watt FE, James OFW, Jones DEJ. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004;97(7):397\u2013406. https:\/\/doi.org\/10.1093\/qjmed\/hch078.","journal-title":"QJM"},{"issue":"4\u20135","key":"129_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.autrev.2014.01.029","volume":"13","author":"MW Laass","year":"2014","unstructured":"Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn\u2019s disease. Autoimmun Rev. 2014;13(4\u20135):467\u201371. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.029.","journal-title":"Autoimmun Rev"},{"issue":"4\u20135","key":"129_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","volume":"13","author":"K Conrad","year":"2014","unstructured":"Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014;13(4\u20135):463\u20136. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.028.","journal-title":"Autoimmun Rev"},{"key":"129_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/gut.39.5.690","volume":"39","author":"S Shivananda","year":"1996","unstructured":"Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut. 1996;39:690\u20137.","journal-title":"Gut"},{"issue":"5","key":"129_CR19","doi-asserted-by":"publisher","first-page":"A372","DOI":"10.1016\/j.autrev.2009.11.008","volume":"9","author":"I Logan","year":"2010","unstructured":"Logan I, Bowlus CL. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev. 2010;9(5):A372\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2009.11.008.","journal-title":"Autoimmun Rev"},{"issue":"10114","key":"129_CR20","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u201378.","journal-title":"Lancet"},{"issue":"1","key":"129_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46\u201354.e42. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.001.","journal-title":"Gastroenterology"},{"issue":"02","key":"129_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1055\/s-0031-1276647","volume":"31","author":"T Karlsen","year":"2011","unstructured":"Karlsen T, Kaser A. Deciphering the genetic predisposition to primary sclerosing cholangitis. Semin Liver Dis. 2011;31(02):188\u2013207. https:\/\/doi.org\/10.1055\/s-0031-1276647.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"129_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","volume":"33","author":"D Joshi","year":"2013","unstructured":"Joshi D, Bjarnason I, Belgaumkar A, et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int. 2013;33(1):53\u201361. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02677.x.","journal-title":"Liver Int"},{"issue":"10","key":"129_CR24","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamasurg.2014.1072","volume":"149","author":"UA Gerlach","year":"2014","unstructured":"Gerlach UA, Vrakas G, Reddy S, et al. Chronic intestinal failure after crohn disease. JAMA Surg. 2014;149(10):1060. https:\/\/doi.org\/10.1001\/jamasurg.2014.1072.","journal-title":"JAMA Surg"},{"issue":"2","key":"129_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc1505689","volume":"373","author":"LISH Beaugerie","year":"2015","unstructured":"Beaugerie LISH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;373(2):194\u20135. https:\/\/doi.org\/10.1056\/NEJMc1505689.","journal-title":"N Engl J Med"},{"issue":"4","key":"129_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/gut.48.4.526","volume":"48","author":"JA Eaden","year":"2001","unstructured":"Eaden JA. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526\u201335. https:\/\/doi.org\/10.1136\/gut.48.4.526.","journal-title":"Gut"},{"issue":"12","key":"129_CR27","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1111\/j.1572-0241.2005.00287.x","volume":"100","author":"T Jess","year":"2005","unstructured":"Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn\u2019s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100(12):2724\u20139. https:\/\/doi.org\/10.1111\/j.1572-0241.2005.00287.x.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"129_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/ng.3745","volume":"49","author":"S-G Ji","year":"2017","unstructured":"Ji S-G, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, M\u00fcller T, Schramm C, Sterneck M, Weism\u00fcller TJ, Gotthardt DN, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma RK, Wijmenga C, Marschall H-U, Milkiewicz P, Pares A, Kontula K, Chazouill\u00e8res O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Floreani A, Gulamhusein AF, Eaton JE, Schreiber S, Coltescu C, Bowlus CL, Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, Sandford RN, Alexander G, Gaffney DJ, Chapman RW, Hirschfield GM, de Andrade M, The UK-PSC Consortium, The International IBD Genetics Consortium, The International PSC Study Group, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269\u201373.","journal-title":"Nat Genet"},{"issue":"12","key":"129_CR29","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ng.717","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci. Nat Genet. 2010;42(12):1118\u201325. https:\/\/doi.org\/10.1038\/ng.717.","journal-title":"Nat Genet"},{"issue":"7422","key":"129_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins L, Ripke S, Weersma RK, et al. Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119\u201324. https:\/\/doi.org\/10.1038\/nature11582.","journal-title":"Nature"},{"issue":"2","key":"129_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0168-8278(00)80061-6","volume":"32","author":"P Angulo","year":"2000","unstructured":"Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol. 2000;32(2):182\u20137. https:\/\/doi.org\/10.1016\/S0168-8278(00)80061-6.","journal-title":"J Hepatol"},{"issue":"5","key":"129_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1084\/jem.117.5.717","volume":"117","author":"P Perlmann","year":"1963","unstructured":"Perlmann P, Broberger O. In vitro studies of ulcerative colitis: cytotoxic action of white blood cells from patients on human fetal colon cells. J Exp Med. 1963;117(5):717\u201333.","journal-title":"J Exp Med"},{"key":"129_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1084\/jem.115.1.13","volume":"115","author":"P Perlmann","year":"1962","unstructured":"Perlmann P, Broberger O. Demonstration of an epithelial antigen in colon by means of fluorescent antibodies from children with ulcerative colitis. J Exp Med. 1962;115:13\u201326.","journal-title":"J Exp Med"},{"key":"129_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1084\/jem.110.5.657","volume":"110","author":"O Broberger","year":"1959","unstructured":"Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med. 1959;110:657\u201374.","journal-title":"J Exp Med"},{"key":"129_CR35","first-page":"30","volume":"76","author":"JA Snook","year":"1989","unstructured":"Snook JA, Chapman RW, Fleming K, et al. Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn\u2019s disease and primary sclerosing cholangitis. Clin Exp Immunol. 1989;76:30\u20133.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"129_CR36","first-page":"23","volume":"91","author":"H Nielsen","year":"1983","unstructured":"Nielsen H, Wiik A, Elmgreen J. Granulocyte specific antinuclear antibodies in ulcerative colitis. Aid in differential diagnosis of inflammatory bowel disease. Acta Pathol Microbiol Immunol Scand C. 1983;91(1):23\u20136.","journal-title":"Acta Pathol Microbiol Immunol Scand C"},{"key":"129_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/gut.27.1.86","volume":"27","author":"RW Chapman","year":"1986","unstructured":"Chapman RW, Cottone M, Selby WS, Shepherd HA, Sherlock S, Jewell DP. Serumautoantibodies, ulcerativecolitisandprimarysclerosingcholangitis. Gut. 1986;27:86\u201391.","journal-title":"Gut."},{"issue":"8093","key":"129_CR38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(78)92648-X","volume":"2","author":"JE Walker","year":"1978","unstructured":"Walker JE. Possible diagnostic test for Crohn\u2019s disease by use of buccal mucosa. Lancet. 1978;2(8093):759\u201360.","journal-title":"Lancet"},{"key":"129_CR39","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1055\/s-2008-1069485","volume":"109","author":"W St\u00f6cker","year":"1984","unstructured":"St\u00f6cker W, Otte M, Ulrich S, et al. Autoantik\u00f6per gegen exokrines Pankreas und gegen intestinale Becherzellen in der Diagnostik des Morbus Crohn und der Colitis ulcerosa. Dtsch Med Wochenschr. 1984;109:1963\u20139.","journal-title":"Dtsch Med Wochenschr"},{"key":"129_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/00365528709089774","volume":"139","author":"W St\u00f6cker","year":"1987","unstructured":"St\u00f6cker W, Otte M, Ulrich S, et al. Autoimmunity to pancreatic juice in Crohn\u2019s disease Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1987;139:41\u201352.","journal-title":"Scand J Gastroenterol"},{"key":"129_CR41","first-page":"319","volume":"30","author":"EM Goischke","year":"1992","unstructured":"Goischke EM, Zilly W. Klinische Bedeutung organspezifischer Antikorper bei Colitis ulcerosa und Morbus Crohn. Z Gastroenterol. 1992;30:319\u201324.","journal-title":"Z Gastroenterol"},{"key":"129_CR42","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/j.1572-0241.1999.01287.x","volume":"94","author":"M Barthet","year":"1999","unstructured":"Barthet M, Hastier P, Bernard JP, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94:2141\u20138.","journal-title":"Am J Gastroenterol"},{"key":"129_CR43","first-page":"1033","volume":"87","author":"SE Spiess","year":"1992","unstructured":"Spiess SE, Braun M, Vogelsang RL, et al. Crohn\u2019s disease of the duodenum complicated by pancreatitis and common bile duct obstruction. Am J Gastroenterol. 1992;87:1033\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"129_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00042737-200501000-00015","volume":"17","author":"FH Klebl","year":"2005","unstructured":"Klebl FH, Bataille F, Huy C, et al. Association of antibodies to exocrine pancreas with subtypes of Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2005;17(1):73\u20137. https:\/\/doi.org\/10.1097\/00042737-200501000-00015.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"129_CR45","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1016\/j.crohns.2012.12.013","volume":"7","author":"D Roggenbuck","year":"2013","unstructured":"Roggenbuck D, Bogdanos D, Conrad K. Loss of tolerance to one or two major targets in Crohn\u2019s disease or just cross-reactivity? J Crohns Colitis. 2013;7(7):e273\u20134. https:\/\/doi.org\/10.1016\/j.crohns.2012.12.013.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"129_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/gut.51.1.120","volume":"51","author":"B Xu","year":"2002","unstructured":"Xu B, Broome U, Ericzon B-G, et al. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut. 2002;51(1):120\u20137. https:\/\/doi.org\/10.1136\/gut.51.1.120.","journal-title":"Gut"},{"issue":"2","key":"129_CR47","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1053\/gast.2000.9366","volume":"119","author":"B Terjung","year":"2000","unstructured":"Terjung B, Spengler U, Sauerbruch T, et al. \u201cAtypical p-ANCA\u201d in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000;119(2):310\u201322. https:\/\/doi.org\/10.1053\/gast.2000.9366.","journal-title":"Gastroenterology"},{"issue":"2","key":"129_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1385\/CRIAI:28:2:115","volume":"28","author":"B Terjung","year":"2005","unstructured":"Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. CRIAI. 2005;28(2):115\u201334. https:\/\/doi.org\/10.1385\/CRIAI:28:2:115.","journal-title":"CRIAI"},{"issue":"3","key":"129_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/hep.1840170310","volume":"17","author":"AH Mulder","year":"1992","unstructured":"Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1992;17(3):411\u20137.","journal-title":"Hepatology"},{"issue":"4","key":"129_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/bega.2001.0209","volume":"15","author":"B Terjung","year":"2001","unstructured":"Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15(4):629\u201342. https:\/\/doi.org\/10.1053\/bega.2001.0209.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"129_CR51","first-page":"483","volume":"52","author":"D Roggenbuck","year":"2014","unstructured":"Roggenbuck D, Reinhold D, Schierack P, et al. Crohn\u2019s disease specific pancreatic antibodies: clinical and pathophysiological challenges. Clin Chem Lab Med. 2014;52:483\u201394.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"129_CR52","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/ecco-jcc\/jjv087","volume":"9","author":"M Papp","year":"2015","unstructured":"Papp M, Sipeki N, Tornai T, et al. Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of crohn\u2019s patients: the importance of specific target antigens GP2 and CUZD1. J Crohns Colitis. 2015;9(8):659\u201368. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv087.","journal-title":"J Crohns Colitis"},{"key":"129_CR53","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/gut.32.10.1192","volume":"32","author":"F Seibold","year":"1991","unstructured":"Seibold F, Weber P, Jenss H, et al. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn\u2019s disease. Gut. 1991;32:1192\u20137.","journal-title":"Gut"},{"key":"129_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1365-2362.1999.00414.x","volume":"29","author":"H Fricke","year":"1999","unstructured":"Fricke H, Birkhofer A, Folwaczny C, et al. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn\u2019s disease. Eur J Clin Invest. 1999;29:41\u20135.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"129_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.crohns.2010.10.009","volume":"5","author":"A Koutsoumpas","year":"2011","unstructured":"Koutsoumpas A, Polymeros D, Tsiamoulos Z, et al. Peculiar antibody reactivity to human connexin 37 and its microbial mimics in patients with Crohn\u2019s disease. J Crohns Colitis. 2011;5(2):101\u20139. https:\/\/doi.org\/10.1016\/j.crohns.2010.10.009.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"129_CR56","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ibd.21508","volume":"17","author":"N Vermeulen","year":"2011","unstructured":"Vermeulen N, de B\u00e9eck KO, Vermeire S, et al. Identification of a novel autoantigen in inflammatory bowel disease by protein microarray. Inflamm Bowel Dis. 2011;17(6):1291\u2013300. https:\/\/doi.org\/10.1002\/ibd.21508.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"129_CR57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/gut.52.4.535","volume":"52","author":"H Saito","year":"2003","unstructured":"Saito H, Fukuda Y, Katsuragi K, Tanaka M, Satomi M, Shimoyama T, Saito T, Tachikawa T. Isolation of peptides useful for differential diagnosis of Crohn\u2019s disease and ulcerative colitis. Gut. 2003;52(4):535\u201340.","journal-title":"Gut"},{"key":"129_CR58","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1136\/gut.2008.162495","volume":"58","author":"D Roggenbuck","year":"2009","unstructured":"Roggenbuck D, Hausdorf G, Martinez-Gamboa L, et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn\u2019s disease. Gut. 2009;58:1620\u20138.","journal-title":"Gut"},{"issue":"10","key":"129_CR59","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.crohns.2012.10.011","volume":"7","author":"L Komorowski","year":"2013","unstructured":"Komorowski L, Teegen B, Probst C, et al. Autoantibodies against exocrine pancreas in Crohn\u2019s disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis. 2013;7(10):780\u201390. https:\/\/doi.org\/10.1016\/j.crohns.2012.10.011.","journal-title":"J Crohns Colitis"},{"key":"129_CR60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/gut.40.4.481","volume":"40","author":"F Seibold","year":"1997","unstructured":"Seibold F, M\u00f6rk H, Tanza S, et al. Pancreatic autoantibodies in Crohn\u2019s disease: a family study. Gut. 1997;40:481\u20134.","journal-title":"Gut"},{"key":"129_CR61","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00054725-200411000-00012","volume":"10","author":"S Joossens","year":"2004","unstructured":"Joossens S, Vermeire S, van Steen K, et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:771\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"129_CR62","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/b978-0-12-407681-5.00006-4","volume":"60","author":"D Roggenbuck","year":"2013","unstructured":"Roggenbuck D, Reinhold D, Werner L, et al. Glycoprotein 2 antibodies in Crohn\u2019s disease. Adv Clin Chem. 2013;60:187\u2013208. https:\/\/doi.org\/10.1016\/b978-0-12-407681-5.00006-4.","journal-title":"Adv Clin Chem"},{"issue":"2","key":"129_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.autrev.2011.09.004","volume":"11","author":"DP Bogdanos","year":"2011","unstructured":"Bogdanos DP, Rigopoulou EI, Smyk DS, et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn\u2019s disease specific-pancreatic autoantibodies. Autoimmun Rev. 2011;11(2):143\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2011.09.004.","journal-title":"Autoimmun Rev"},{"key":"129_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/bs.acc.2016.06.002","volume":"77","author":"D Roggenbuck","year":"2016","unstructured":"Roggenbuck D, Reinhold D, Baumgart DC, et al. Autoimmunity in crohn\u2019s disease\u2014a putative stratification factor of the clinical phenotype. Adv Clin Chem. 2016;77:77\u2013101. https:\/\/doi.org\/10.1016\/bs.acc.2016.06.002.","journal-title":"Adv Clin Chem"},{"issue":"6","key":"129_CR65","doi-asserted-by":"publisher","first-page":"e014843","DOI":"10.1136\/bmjopen-2016-014843","volume":"7","author":"C Deng","year":"2017","unstructured":"Deng C, Li W, Li J, et al. Diagnostic value of the antiglycoprotein-2 antibody for Crohn\u2019s disease: a PRISMA-compliant systematic review and meta-analysis. BMJ Open. 2017;7(6):e014843. https:\/\/doi.org\/10.1136\/bmjopen-2016-014843.","journal-title":"BMJ Open"},{"issue":"2","key":"129_CR66","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3748\/wjg.v26.i2.246","volume":"26","author":"K Gkiouras","year":"2020","unstructured":"Gkiouras K, Grammatikopoulou MG, Theodoridis X, et al. Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: a meta-analysis. World J Gastroenterol. 2020;26(2):246\u201365. https:\/\/doi.org\/10.3748\/wjg.v26.i2.246.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"129_CR67","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1038\/ctg.2018.1","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Luo J, Wu Z, et al. Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Beh\u00e7et\u2019s disease. Clin Transl Gastroenterol. 2018;9(2):e133. https:\/\/doi.org\/10.1038\/ctg.2018.1.","journal-title":"Clin Transl Gastroenterol"},{"key":"129_CR68","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cca.2014.12.010","volume":"441","author":"P Pavlidis","year":"2014","unstructured":"Pavlidis P, Shums Z, Koutsoumpas AL, et al. Diagnostic and clinical significance of Crohn\u2019s disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. Clin Chim Acta. 2014;441:176\u201381. https:\/\/doi.org\/10.1016\/j.cca.2014.12.010.","journal-title":"Clin Chim Acta"},{"key":"129_CR69","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-230X-12-102","volume":"12","author":"DP Bogdanos","year":"2012","unstructured":"Bogdanos DP, Roggenbuck D, Reinhold D, et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohns disease. BMC Gastroenterol. 2012;12:102.","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"129_CR70","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1097\/MIB.0000000000000936","volume":"22","author":"F Degenhardt","year":"2016","unstructured":"Degenhardt F, Dirmeier A, Lopez R, et al. Serologic anti-GP2 antibodies are associated with genetic polymorphisms, fibrostenosis, and need for surgical resection in crohn\u2019s disease. Inflamm Bowel Dis. 2016;22(11):2648\u201357. https:\/\/doi.org\/10.1097\/MIB.0000000000000936.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"129_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/gutjnl-2016-312518","volume":"67","author":"M Weiser","year":"2018","unstructured":"Weiser M, Simon JM, Kochar B, et al. Molecular classification of Crohn\u2019s disease reveals two clinically relevant subtypes. Gut. 2018;67(1):36\u201342. https:\/\/doi.org\/10.1136\/gutjnl-2016-312518.","journal-title":"Gut"},{"key":"129_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4137\/CGast.S38203","volume":"9","author":"M Cappello","year":"2016","unstructured":"Cappello M, Morreale GC. The role of laboratory tests in crohn\u2019s disease. Clin Med Insights Gastroenterol. 2016;9:51\u201362. https:\/\/doi.org\/10.4137\/CGast.S38203.","journal-title":"Clin Med Insights Gastroenterol"},{"issue":"6","key":"129_CR73","doi-asserted-by":"publisher","first-page":"e0128104","DOI":"10.1371\/journal.pone.0128104","volume":"10","author":"MW Laass","year":"2015","unstructured":"Laass MW, R\u00f6ber N, Range U, et al. Loss and gain of tolerance to pancreatic glycoprotein 2 in celiac disease. PLoS ONE. 2015;10(6):e0128104. https:\/\/doi.org\/10.1371\/journal.pone.0128104.","journal-title":"PLoS ONE"},{"issue":"9","key":"129_CR74","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1515\/cclm-2014-0238","volume":"53","author":"D Roggenbuck","year":"2015","unstructured":"Roggenbuck D, Vermeire S, Hoffman I, et al. Evidence of Crohn\u2019s disease-related anti-glycoprotein 2 antibodies in patients with celiac disease. Clin Chem Lab Med. 2015;53(9):1349\u201357. https:\/\/doi.org\/10.1515\/cclm-2014-0238.","journal-title":"Clin Chem Lab Med"},{"key":"129_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15403\/jgld.2014.1121.232.sg1","volume":"23","author":"S Gross","year":"2014","unstructured":"Gross S, Bakker SF, van Bodegraven AA, et al. Increased IgA glycoprotein-2 specific antibody titres in refractory CD. J Gastrointest Liver Dis. 2014;23:1\u20137.","journal-title":"J Gastrointest Liver Dis"},{"issue":"2","key":"129_CR76","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1515\/cclm-2015-0376","volume":"54","author":"P Pavlidis","year":"2016","unstructured":"Pavlidis P, Komorowski L, Teegen B, et al. Diagnostic and clinical significance of Crohn\u2019s disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies. Clin Chem Lab Med. 2016;54(2):249\u201356. https:\/\/doi.org\/10.1515\/cclm-2015-0376.","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"129_CR77","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1097\/MIB.0000000000000564","volume":"21","author":"MA Michaels","year":"2015","unstructured":"Michaels MA, Jendrek ST, Korf T, et al. Pancreatic autoantibodies against CUZD1 and GP2 are associated with distinct clinical phenotypes of crohn\u2019s disease. Inflamm Bowel Dis. 2015;21(12):2864\u201372. https:\/\/doi.org\/10.1097\/MIB.0000000000000564.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"129_CR78","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1515\/cclm-2016-1120","volume":"55","author":"S Farkona","year":"2017","unstructured":"Farkona S, Soosaipillai A, Filippou P, et al. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases. Clin Chem Lab Med. 2017;55(10):1574\u201381. https:\/\/doi.org\/10.1515\/cclm-2016-1120.","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"129_CR79","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1016\/j.crohns.2013.03.009","volume":"7","author":"L Werner","year":"2013","unstructured":"Werner L, Sturm A, Roggenbuck D, et al. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch. J Crohns Colitis. 2013;7(11):e522\u201332. https:\/\/doi.org\/10.1016\/j.crohns.2013.03.009.","journal-title":"J Crohns Colitis"},{"issue":"11\u201312","key":"129_CR80","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/apt.15034","volume":"48","author":"D Cummings","year":"2018","unstructured":"Cummings D, Cruise M, Lopez R, et al. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn\u2019s disease of the pouch. Aliment Pharmacol Ther. 2018;48(11\u201312):1251\u20139. https:\/\/doi.org\/10.1111\/apt.15034.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"129_CR81","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.clinre.2014.12.001","volume":"39","author":"C Liaskos","year":"2015","unstructured":"Liaskos C, Spyrou V, Athanasiou LV, et al. Crohn\u2019s disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis. Clin Res Hepatol Gastroenterol. 2015;39(3):384\u201390. https:\/\/doi.org\/10.1016\/j.clinre.2014.12.001.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"129_CR82","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/08916934.2013.786047","volume":"46","author":"C Liaskos","year":"2013","unstructured":"Liaskos C, Spyrou V, Roggenbuck D, et al. Crohn\u2019s disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease. Autoimmunity. 2013;46(6):388\u201394. https:\/\/doi.org\/10.3109\/08916934.2013.786047.","journal-title":"Autoimmunity"},{"key":"129_CR83","doi-asserted-by":"publisher","first-page":"30002","DOI":"10.1016\/j.clinre.2019.12.013","volume":"20","author":"C Liaskos","year":"2020","unstructured":"Liaskos C, Gkoutzourelas A, Spyrou V, et al. Pancreatic anti-GP2 and anti-Saccharomyces cerevisiae antibodies in ruminants with paratuberculosis: a better understanding of the immunopathogenesis of Crohn\u2019s disease. Clin Res Hepatol Gastroenterol. 2020;20:30002\u20134. https:\/\/doi.org\/10.1016\/j.clinre.2019.12.013.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"129_CR84","volume-title":"Anti-intestinal goblet cell antibodies","year":"2014","unstructured":"Conrad K, St\u00f6cker W, editors. Anti-intestinal goblet cell antibodies. Amsterdam: Elsevier; 2014."},{"key":"129_CR85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1749-6632.2009.04752.x","volume":"1173","author":"B Teegen","year":"2009","unstructured":"Teegen B, Niemann S, Probst C, et al. DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. Ann N Y Acad Sci. 2009;1173:161\u20135.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"129_CR86","doi-asserted-by":"publisher","first-page":"e0194166","DOI":"10.1371\/journal.pone.0194166","volume":"13","author":"G Kovacs","year":"2018","unstructured":"Kovacs G, Sipeki N, Suga B, et al. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. PLoS ONE. 2018;13(3):e0194166. https:\/\/doi.org\/10.1371\/journal.pone.0194166.","journal-title":"PLoS ONE"},{"issue":"5","key":"129_CR87","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/gut.32.5.504","volume":"32","author":"L Biancone","year":"1991","unstructured":"Biancone L, Wise LS, Das KM. The presence in experimental animals of a colon specific Mr 40,000 protein(s) with relevance to ulcerative colitis. Gut. 1991;32(5):504\u20138.","journal-title":"Gut"},{"key":"129_CR88","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cca.2013.06.005","volume":"424","author":"M Mahler","year":"2013","unstructured":"Mahler M, Bogdanos DP, Pavlidis P, et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta. 2013;424:267\u201373. https:\/\/doi.org\/10.1016\/j.cca.2013.06.005.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"129_CR89","doi-asserted-by":"publisher","first-page":"e0208974","DOI":"10.1371\/journal.pone.0208974","volume":"13","author":"MP Horn","year":"2018","unstructured":"Horn MP, Peter AM, Righini Grunder F, et al. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn\u2019s disease. PLoS ONE. 2018;13(12):e0208974. https:\/\/doi.org\/10.1371\/journal.pone.0208974.","journal-title":"PLoS ONE"},{"issue":"1","key":"129_CR90","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12016-012-8349-4","volume":"45","author":"MT Arias-Loste","year":"2013","unstructured":"Arias-Loste MT, Bonilla G, Moraleja I, et al. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol. 2013;45(1):109\u201316. https:\/\/doi.org\/10.1007\/s12016-012-8349-4.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"129_CR91","doi-asserted-by":"publisher","first-page":"e107743","DOI":"10.1371\/journal.pone.0107743","volume":"9","author":"M Sowa","year":"2014","unstructured":"Sowa M, Grossmann K, Kn\u00fctter I, et al. Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. PLoS ONE. 2014;9(9):e107743. https:\/\/doi.org\/10.1371\/journal.pone.0107743.","journal-title":"PLoS ONE"},{"issue":"11","key":"129_CR92","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","volume":"13","author":"X Bossuyt","year":"2017","unstructured":"Bossuyt X, Cohen Tervaert J-W, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683\u201392. https:\/\/doi.org\/10.1038\/nrrheum.2017.140.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"129_CR93","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1053\/j.gastro.2007.01.039","volume":"132","author":"A Karrar","year":"2007","unstructured":"Karrar A, Broom\u00e9 U, S\u00f6dergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology. 2007;132(4):1504\u201314. https:\/\/doi.org\/10.1053\/j.gastro.2007.01.039.","journal-title":"Gastroenterology"},{"key":"129_CR94","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaut.2018.10.004","volume":"95","author":"B Terziroli Beretta-Piccoli","year":"2018","unstructured":"Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: a comprehensive overview. J Autoimmun. 2018;95:144\u201358. https:\/\/doi.org\/10.1016\/j.jaut.2018.10.004.","journal-title":"J Autoimmun"},{"issue":"6","key":"129_CR95","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/gut.2008.157818","volume":"59","author":"B Terjung","year":"2010","unstructured":"Terjung B, S\u00f6hne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut. 2010;59(6):808\u201316. https:\/\/doi.org\/10.1136\/gut.2008.157818.","journal-title":"Gut"},{"issue":"11","key":"129_CR96","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1136\/gut.2010.222646","volume":"60","author":"KO de Be\u00e9ck","year":"2011","unstructured":"de Be\u00e9ck KO, van den Bergh K, Vermeire S, et al. Immune reactivity to \u03b2-tubulin isotype 5 and vesicular integral-membrane protein 36 in patients with autoimmune gastrointestinal disorders. Gut. 2011;60(11):1601\u20132. https:\/\/doi.org\/10.1136\/gut.2010.222646.","journal-title":"Gut"},{"issue":"1","key":"129_CR97","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12876-018-0787-x","volume":"18","author":"BE Preu\u00df","year":"2018","unstructured":"Preu\u00df BE, Berg CP, Werner C, et al. Sulphite oxidase (SO)\u2014a mitochondrial autoantigen as target for humoral and cellular immune reactions in primary sclerosing cholangitis. BMC Gastroenterol. 2018;18(1):58. https:\/\/doi.org\/10.1186\/s12876-018-0787-x.","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"129_CR98","doi-asserted-by":"publisher","first-page":"e112877","DOI":"10.1371\/journal.pone.0112877","volume":"9","author":"LM Stinton","year":"2014","unstructured":"Stinton LM, Bentow C, Mahler M, et al. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). PLoS ONE. 2014;9(11):e112877. https:\/\/doi.org\/10.1371\/journal.pone.0112877.","journal-title":"PLoS ONE"},{"issue":"11","key":"129_CR99","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2169\/internalmedicine.9724-17","volume":"57","author":"T Yamamoto","year":"2018","unstructured":"Yamamoto T, Ryuzaki H, Kobayashi S, et al. Suspected hepatically localized granulomatosis with polyangiitis. Intern Med. 2018;57(11):1583\u201390. https:\/\/doi.org\/10.2169\/internalmedicine.9724-17.","journal-title":"Intern Med"},{"issue":"1","key":"129_CR100","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/gutjnl-2016-311739","volume":"66","author":"ST Jendrek","year":"2017","unstructured":"Jendrek ST, Gotthardt D, Nitzsche T, et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66(1):137\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2016-311739.","journal-title":"Gut"},{"issue":"1","key":"129_CR101","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41598-017-18622-1","volume":"8","author":"T Tornai","year":"2018","unstructured":"Tornai T, Tornai D, Sipeki N, et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018;8(1):399. https:\/\/doi.org\/10.1038\/s41598-017-18622-1.","journal-title":"Sci Rep"},{"key":"129_CR102","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cca.2015.01.018","volume":"442","author":"D Roggenbuck","year":"2015","unstructured":"Roggenbuck D, R\u00f6ber N, Bogdanos DP, et al. Autoreactivity to isoforms of glycoprotein 2 in inflammatory bowel disease. Clin Chim Acta. 2015;442:82\u20133. https:\/\/doi.org\/10.1016\/j.cca.2015.01.018.","journal-title":"Clin Chim Acta"},{"issue":"9","key":"129_CR103","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1097\/MIB.0000000000001159","volume":"23","author":"N R\u00f6ber","year":"2017","unstructured":"R\u00f6ber N, No\u00df L, Goihl A, et al. Autoantibodies against glycoprotein 2 isoforms in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(9):1624\u201336. https:\/\/doi.org\/10.1097\/MIB.0000000000001159.","journal-title":"Inflamm Bowel Dis"},{"key":"129_CR104","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3389\/fimmu.2018.01959","volume":"9","author":"M Sowa","year":"2018","unstructured":"Sowa M, Kolenda R, Baumgart DC, et al. Mucosal autoimmunity to cell-bound GP2 isoforms is a sensitive marker in PSC and associated with the clinical phenotype. Front Immunol. 2018;9:1959. https:\/\/doi.org\/10.3389\/fimmu.2018.01959.","journal-title":"Front Immunol"},{"key":"129_CR105","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2220\/biomedres.37.351","volume":"37","author":"S Kimura","year":"2016","unstructured":"Kimura S, Nio-Kobayashi J, Kishimoto A, et al. The broad distribution of GP2 in mucous glands and secretory products. Biomed Res. 2016;37:351\u20138.","journal-title":"Biomed Res"},{"key":"129_CR106","doi-asserted-by":"publisher","first-page":"968041","DOI":"10.1155\/2013\/968041","volume":"2013","author":"C Liaskos","year":"2013","unstructured":"Liaskos C, Rigopoulou EI, Orfanidou T, et al. CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases. Clin Dev Immunol. 2013;2013:968041. https:\/\/doi.org\/10.1155\/2013\/968041.","journal-title":"Clin Dev Immunol"},{"key":"129_CR107","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0005-2736(78)90189-X","volume":"508","author":"RA Ronzio","year":"1978","unstructured":"Ronzio RA, Kronquist KE, Lewis DS, et al. Glycoprotein synthesis in the adult rat pancreas. IV. Subcellular distribution of membrane glycoproteins. Biochim Biophys Acta. 1978;508:65\u201384.","journal-title":"Biochim Biophys Acta"},{"key":"129_CR108","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1432-1033.1983.tb07484.x","volume":"133","author":"JR Havinga","year":"1983","unstructured":"Havinga JR, Strous GJ, Poort C. Biosynthesis of the major glycoprotein associated with zymogen-granule membranes in the pancreas. Eur J Biochem. 1983;133:449\u201354.","journal-title":"Eur J Biochem"},{"key":"129_CR109","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/0006-291X(88)90213-6","volume":"154","author":"D LeBel","year":"1988","unstructured":"LeBel D, Beattie M. The major protein of pancreatic zymogen granule membranes (GP-2) is anchored via covalent bonds to phosphatidylinositol. Biochem Biophys Res Commun. 1988;154:818\u201323.","journal-title":"Biochem Biophys Res Commun"},{"issue":"48","key":"129_CR110","doi-asserted-by":"publisher","first-page":"50274","DOI":"10.1074\/jbc.M410599200","volume":"279","author":"S Yu","year":"2004","unstructured":"Yu S, Michie SA, Lowe AW. Absence of the major zymogen granule membrane protein, GP2, does not affect pancreatic morphology or secretion. J Biol Chem. 2004;279(48):50274\u20139. https:\/\/doi.org\/10.1074\/jbc.M410599200.","journal-title":"J Biol Chem"},{"key":"129_CR111","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1242\/jcs.113.12.2233","volume":"113","author":"K Schmidt","year":"2000","unstructured":"Schmidt K, Dartsch H, Linder D, Kern H-F, Kleene R. The submembranous network of zymogen granules. J Cell Sci. 2000;113:2233\u201342.","journal-title":"J Cell Sci"},{"issue":"16","key":"129_CR112","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1002\/j.1460-2075.1994.tb06680.x","volume":"13","author":"V Colomer","year":"1994","unstructured":"Colomer V, Lal K, Hoops TC, Rindler MJ. Exocrine granule specific packaging signals are present in the polypeptide moiety of the pancreatic granule membrane protein GP2 and in amylase: implications for protein targeting to secretory granules. EMBO J. 1994;13(16):3711\u20139.","journal-title":"EMBO J"},{"issue":"7270","key":"129_CR113","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature08529","volume":"462","author":"K Hase","year":"2009","unstructured":"Hase K, Kawano K, Nochi T, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature. 2009;462(7270):226\u201330. https:\/\/doi.org\/10.1038\/nature08529.","journal-title":"Nature"},{"issue":"12","key":"129_CR114","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.4049\/jimmunol.180.12.7840","volume":"180","author":"K Terahara","year":"2008","unstructured":"Terahara K, Yoshida M, Igarashi O, Nochi T, Pontes GS, Hase K, Ohno H, Kurokawa S, Mejima M, Takayama N, Yuki Y, Lowe AW, Kiyono H. Comprehensive gene expression profiling of Peyer\u2019s patch M cells, villous M-like cells, and intestinal epithelial cells. J Immunol. 2008;180(12):7840\u20136.","journal-title":"J Immunol"},{"key":"129_CR115","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3389\/fimmu.2019.02345","volume":"10","author":"N Kobayashi","year":"2019","unstructured":"Kobayashi N, Takahashi D, Takano S, et al. The roles of Peyer\u2019s patches and microfold cells in the gut immune system: relevance to autoimmune diseases. Front Immunol. 2019;10:2345. https:\/\/doi.org\/10.3389\/fimmu.2019.02345.","journal-title":"Front Immunol"},{"issue":"3","key":"129_CR116","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/mi.2014.99","volume":"8","author":"S Kimura","year":"2015","unstructured":"Kimura S, Yamakami-Kimura M, Obata Y, et al. Visualization of the entire differentiation process of murine M cells: suppression of their maturation in cecal patches. Mucosal Immunol. 2015;8(3):650\u201360. https:\/\/doi.org\/10.1038\/mi.2014.99.","journal-title":"Mucosal Immunol"},{"issue":"8","key":"129_CR117","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/ni.2352","volume":"13","author":"T Kanaya","year":"2012","unstructured":"Kanaya T, Hase K, Takahashi D, et al. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat Immunol. 2012;13(8):729\u201336. https:\/\/doi.org\/10.1038\/ni.2352.","journal-title":"Nat Immunol"},{"key":"129_CR118","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1196\/annals.1326.028","volume":"1072","author":"E Gullberg","year":"2006","unstructured":"Gullberg E, S\u00f6derholm JD. Peyer\u2019s patches and M cells as potential sites of the inflammatory onset in Crohn\u2019s disease. Ann N Y Acad Sci. 2006;1072:218\u201332. https:\/\/doi.org\/10.1196\/annals.1326.028.","journal-title":"Ann N Y Acad Sci"},{"issue":"8779","key":"129_CR119","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/0140-6736(91)92282-7","volume":"338","author":"G Olaison","year":"1991","unstructured":"Olaison G, Smedh K, Sj\u00f6dahl R. Recurrence of Crohn\u2019s disease in the neo-terminal ileum and colonic factors. Lancet. 1991;338(8779):1401. https:\/\/doi.org\/10.1016\/0140-6736(91)92282-7.","journal-title":"Lancet"},{"issue":"3","key":"129_CR120","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/00054725-200205000-00004","volume":"8","author":"HJ van Kruiningen","year":"2002","unstructured":"van Kruiningen HJ, West AB, Freda BJ, et al. Distribution of Peyer\u2019s patches in the distal ileum. Inflamm Bowel Dis. 2002;8(3):180\u20135. https:\/\/doi.org\/10.1097\/00054725-200205000-00004.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"129_CR121","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1053\/j.gastro.2006.02.004","volume":"130","author":"LA Garc\u00eda Rodr\u00edguez","year":"2006","unstructured":"Garc\u00eda Rodr\u00edguez LA, Ruig\u00f3mez A, Pan\u00e9s J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. 2006;130(6):1588\u201394. https:\/\/doi.org\/10.1053\/j.gastro.2006.02.004.","journal-title":"Gastroenterology"},{"issue":"6","key":"129_CR122","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.4049\/jimmunol.1103190","volume":"189","author":"L Werner","year":"2012","unstructured":"Werner L, Paclik D, Fritz C, et al. Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J Immunol. 2012;189(6):2774\u201383. https:\/\/doi.org\/10.4049\/jimmunol.1103190.","journal-title":"J Immunol"},{"issue":"3","key":"129_CR123","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/gutjnl-2014-307854","volume":"64","author":"P Schierack","year":"2015","unstructured":"Schierack P, R\u00f6diger S, Kolenda R, et al. Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (GP2). Gut. 2015;64(3):517\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2014-307854.","journal-title":"Gut"},{"key":"129_CR124","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-230X-9-58","volume":"9","author":"S Yu","year":"2009","unstructured":"Yu S, Lowe AW. The pancreatic zymogen granule membrane protein, GP2, binds Escherichia coli Type 1 fimbriae. BMC Gastroenterol. 2009;9:58. https:\/\/doi.org\/10.1186\/1471-230X-9-58.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"129_CR125","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4161\/gmic.1.6.14078","volume":"1","author":"H Ohno","year":"2010","unstructured":"Ohno H, Hase K. Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity. Gut Microbes. 2010;1(6):407\u201310. https:\/\/doi.org\/10.4161\/gmic.1.6.14078.","journal-title":"Gut Microbes"},{"issue":"2","key":"129_CR126","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cellimm.2010.12.001","volume":"267","author":"MA H\u00f6lzl","year":"2011","unstructured":"H\u00f6lzl MA, Hofer J, Kovarik JJ, et al. The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I). Cell Immunol. 2011;267(2):88\u201393.","journal-title":"Cell Immunol"},{"issue":"2","key":"129_CR127","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2004.04.061","volume":"127","author":"A Darfeuille-Michaud","year":"2004","unstructured":"Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn\u2019s disease. Gastroenterology. 2004;127(2):412\u201321. https:\/\/doi.org\/10.1053\/j.gastro.2004.04.061.","journal-title":"Gastroenterology"},{"issue":"1","key":"129_CR128","doi-asserted-by":"publisher","first-page":"e1003141","DOI":"10.1371\/journal.ppat.1003141","volume":"9","author":"N Dreux","year":"2013","unstructured":"Dreux N, Denizot J, Martinez-Medina M, et al. Point mutations in FimH adhesin of Crohn\u2019s disease-associated adherent-invasive Escherichia coli enhance intestinal inflammatory response. PLoS Pathog. 2013;9(1):e1003141. https:\/\/doi.org\/10.1371\/journal.ppat.1003141.","journal-title":"PLoS Pathog"},{"issue":"3","key":"129_CR129","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1172\/jci44632","volume":"121","author":"B Chassaing","year":"2011","unstructured":"Chassaing B, Rolhion N, de Vall\u00e9e A, et al. Crohn disease-associated adherent-invasive E. coli bacteria target mouse and human Peyer\u2019s patches via long polar fimbriae. J Clin Invest. 2011;121(3):966\u201375. https:\/\/doi.org\/10.1172\/jci44632.","journal-title":"J Clin Invest"},{"issue":"11","key":"129_CR130","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1016\/j.crohns.2013.06.017","volume":"7","author":"L Werner","year":"2013","unstructured":"Werner L, Roggenbuck D, Dotan I. Reply to Dr. Pavlidis et al\u2019s letter. J Crohns Colitis. 2013;7(11):e604\u20135. https:\/\/doi.org\/10.1016\/j.crohns.2013.06.017.","journal-title":"J Crohns Colitis"},{"key":"129_CR131","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cca.2009.06.035","volume":"408","author":"G Hausdorf","year":"2009","unstructured":"Hausdorf G, Roggenbuck D, Feist E, et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA\u2014revival of a disease-activity marker in autoimmune hepatitis. Clin Chim Acta. 2009;408:19\u201324.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"129_CR132","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.autrev.2012.04.005","volume":"12","author":"EI Rigopoulou","year":"2012","unstructured":"Rigopoulou EI, Roggenbuck D, Smyk DS, et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev. 2012;12(2):260\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2012.04.005.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"129_CR133","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1172\/JCI116602","volume":"92","author":"SD Freedman","year":"1993","unstructured":"Freedman SD, Sakamoto K, Venu RP. GP2, the homologue to the renal cast protein uromodulin, is a major component of intraductal plugs in chronic pancreatitis. J Clin Invest. 1993;92(1):83\u201390. https:\/\/doi.org\/10.1172\/JCI116602.","journal-title":"J Clin Invest"},{"key":"129_CR134","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jcp.19.4.392","volume":"19","author":"EG McQueen","year":"1966","unstructured":"McQueen EG, Engel GB. Factors determining the aggregation of urinary mucoprotein. J Clin Pathol. 1966;19:392\u20136.","journal-title":"J Clin Pathol"},{"key":"129_CR135","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0002-9440(10)64142-9","volume":"158","author":"WZ Ying","year":"2001","unstructured":"Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001;158:1859\u201366.","journal-title":"Am J Pathol"},{"issue":"8","key":"129_CR136","doi-asserted-by":"publisher","first-page":"e0182924","DOI":"10.1371\/journal.pone.0182924","volume":"12","author":"P Pereira","year":"2017","unstructured":"Pereira P, Aho V, Arola J, et al. Bile microbiota in primary sclerosing cholangitis: impact on disease progression and development of biliary dysplasia. PLoS ONE. 2017;12(8):e0182924. https:\/\/doi.org\/10.1371\/journal.pone.0182924.","journal-title":"PLoS ONE"},{"issue":"3","key":"129_CR137","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000431071","volume":"31","author":"J Verdier","year":"2015","unstructured":"Verdier J, Luedde T, Sellge G. Biliary mucosal barrier and microbiome. Viszeralmedizin. 2015;31(3):156\u201361. https:\/\/doi.org\/10.1159\/000431071.","journal-title":"Viszeralmedizin"},{"issue":"2","key":"129_CR138","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","volume":"57","author":"T Folseraas","year":"2012","unstructured":"Folseraas T, Melum E, Rausch P, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol. 2012;57(2):366\u201375. https:\/\/doi.org\/10.1016\/j.jhep.2012.03.031.","journal-title":"J Hepatol"},{"issue":"47","key":"129_CR139","doi-asserted-by":"publisher","first-page":"19030","DOI":"10.1073\/pnas.1106408108","volume":"108","author":"P Rausch","year":"2011","unstructured":"Rausch P, Rehman A, K\u00fcnzel S, et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci USA. 2011;108(47):19030\u20135. https:\/\/doi.org\/10.1073\/pnas.1106408108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"129_CR140","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","volume":"63","author":"K Machiels","year":"2014","unstructured":"Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275\u201383.","journal-title":"Gut"},{"issue":"5","key":"129_CR141","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/gut.2010.223263","volume":"60","author":"M Joossens","year":"2011","unstructured":"Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn\u2019s disease and their unaffected relatives. Gut. 2011;60(5):631\u20137. https:\/\/doi.org\/10.1136\/gut.2010.223263.","journal-title":"Gut"},{"issue":"1","key":"129_CR142","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/gut.2010.213264","volume":"60","author":"D Moussata","year":"2011","unstructured":"Moussata D, Goetz M, Gloeckner A, et al. Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut. 2011;60(1):26\u201333. https:\/\/doi.org\/10.1136\/gut.2010.213264.","journal-title":"Gut"},{"key":"129_CR143","doi-asserted-by":"publisher","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"129_CR144","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1053\/j.gastro.2010.08.049","volume":"139","author":"BP Willing","year":"2010","unstructured":"Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(6):1844\u20131854.e1. https:\/\/doi.org\/10.1053\/j.gastro.2010.08.049.","journal-title":"Gastroenterology"},{"issue":"43","key":"129_CR145","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol H, Pigneur B, Watterlot L, Lakhdari O, Berm\u00fadez-Humar\u00e1n LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blotti\u00e8re HM, Dor\u00e9 J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105(43):16731\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"129_CR146","doi-asserted-by":"publisher","first-page":"389537","DOI":"10.1155\/2013\/389537","volume":"2013","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int. 2013;2013:389537. https:\/\/doi.org\/10.1155\/2013\/389537.","journal-title":"Biomed Res Int"},{"key":"129_CR147","unstructured":"Gell PGH, Coombs RRA (1963) Clinical Aspects of Immunology: Section IV, Chapter 1."},{"issue":"11","key":"129_CR148","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.5858\/arpa.2015-0396-RS","volume":"140","author":"S Ainechi","year":"2016","unstructured":"Ainechi S, Lee H. Updates on precancerous lesions of the biliary tract: biliary precancerous lesion. Arch Pathol Lab Med. 2016;140(11):1285\u20139.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"129_CR149","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/19490976.2014.969977","volume":"5","author":"JL Gommerman","year":"2014","unstructured":"Gommerman JL, Rojas OL, Fritz JH. Re-thinking the functions of IgA(+) plasma cells. Gut Microbes. 2014;5(5):652\u201362. https:\/\/doi.org\/10.4161\/19490976.2014.969977.","journal-title":"Gut Microbes"},{"issue":"7680","key":"129_CR150","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature24302","volume":"551","author":"S Shalapour","year":"2017","unstructured":"Shalapour S, Lin X-J, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017;551(7680):340\u20135. https:\/\/doi.org\/10.1038\/nature24302.","journal-title":"Nature"},{"key":"129_CR151","first-page":"671","volume":"54","author":"H Nagura","year":"1983","unstructured":"Nagura H, Tsutsumi Y, Hasegawa H, et al. IgA plasma cells in biliary mucosa: a likely source of locally synthesized IgA in human hepatic bile. Clin Exp Immunol. 1983;54:671\u201380.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"129_CR152","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ibd.21046","volume":"16","author":"F Rieder","year":"2010","unstructured":"Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn\u2019s disease behavior. Inflamm Bowel Dis. 2010;16(2):263\u201374. https:\/\/doi.org\/10.1002\/ibd.21046.","journal-title":"Inflamm Bowel Dis"},{"key":"129_CR153","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12876-014-0190-1","volume":"14","author":"D Kohoutova","year":"2014","unstructured":"Kohoutova D, Drahosova M, Moravkova P, et al. Anti-outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn\u2019s disease. BMC Gastroenterol. 2014;14:190. https:\/\/doi.org\/10.1186\/s12876-014-0190-1.","journal-title":"BMC Gastroenterol"}],"container-title":["Autoimmunity Highlights"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13317-020-00129-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13317-020-00129-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13317-020-00129-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T22:13:23Z","timestamp":1666131203000},"score":1,"resource":{"primary":{"URL":"https:\/\/autoimmunhighlights.biomedcentral.com\/articles\/10.1186\/s13317-020-00129-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1186\/s13317-020-00129-x","relation":{},"ISSN":["2038-0305","2038-3274"],"issn-type":[{"value":"2038-0305","type":"print"},{"value":"2038-3274","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"15 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SL and DR are employees of Medipan GmbH. DR are a shareholder of GA Generic Assays GmbH and Medipan GmbH. Both companies are diagnostic manufacturers. All other authors declare that they have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}